CSPC Pharmaceutical's (HKG:1093) SYS6037 Injection obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S.
The mpox vaccine was co-developed by the company and the Institute of Microbiology, the Chinese Academy of Sciences, according to a Monday Hong Kong bourse filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments